DE3414752C2 - - Google Patents
Info
- Publication number
- DE3414752C2 DE3414752C2 DE3414752A DE3414752A DE3414752C2 DE 3414752 C2 DE3414752 C2 DE 3414752C2 DE 3414752 A DE3414752 A DE 3414752A DE 3414752 A DE3414752 A DE 3414752A DE 3414752 C2 DE3414752 C2 DE 3414752C2
- Authority
- DE
- Germany
- Prior art keywords
- group
- compound
- formula
- hydrogen atom
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/40—Halogenated unsaturated alcohols
- C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/17—Unsaturated ethers containing halogen
- C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/17—Unsaturated ethers containing halogen
- C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
- C07C43/1742—Unsaturated ethers containing halogen containing six-membered aromatic rings with halogen atoms bound to the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1782—Unsaturated ethers containing hydroxy or O-metal groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D303/40—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by ester radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/54—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Description
wobei L, R⁵ und R⁶ die zuvor gegebenen Bedeutungen besitzen, mit einem Amin der allgemeinen Formel (VIII)
[B] - CX-ER (9 : 1)
[C] - ER-CX-Triethylamin (60 : 40 : 1)
[D] - CX-ER (1 : 4)
[E] - CX-EA (19 : 1)
[F] - CX-ER (4 : 1)
[G] - ER
[H] - EA
[I] - EA-Methanol-Triethylamin (9 : 1 : 0,1)
[J] - CX-ER (7 : 3)
[K] - CX-EA (9 : 1)
[L] - CX-ER (3 : 1)
[M] - EA-CH₂OH-NH₃ (9 : 1 : 0,1)
[N] - EA-CH₃OH (9 : 1)
[O] - CX-ER (1 : 1).
gefunden: C: 81,60; H: 10,1; N: 4,2
berechnet: C: 81,35; H: 9,80; N: 4,15%.
TLC EN [N] Rf 0,31.
Claims (4)
- (1) (a) ein Amin der allgemeinen Formel: worin R³, R⁵ und R⁶ jeweils ein Wasserstoffatom oder eine Schutzgruppe bedeuten und R⁴ für ein Wasserstoffatom steht, mit einem Alkylierungsmittel der allgemeinen Form: worin L eine abspaltbare Gruppe darstellt, alkyliert oder
- (1) (b) ein Amin der allgemeinen Formel (II), worin R⁴ ein Wasserstoffatom oder eine bei den Reaktionsbedingungen darin umwandelbare Gruppe bedeutet, mit einer Verbindung der Formel: in Anwesenheit eines Reduktionsmittels alkyliert und anschließend möglicherweise vorhandene Schutzgruppen entfernt; oder
- (2) ein Zwischenprodukt der allgemeinen Formel:
worin R⁵ für ein Wasserstoffatom oder eine Schutzgruppe
steht und mindestens einer der Substituenten X, X¹, X², X³
und X⁴ eine reduzierbare Gruppe bedeutet, wobei X für die
Gruppe -CO₂R⁷, worin R⁷ ein Wasserstoffatom bedeutet, oder
für -CHO steht, X¹ für eine Gruppe -C=O steht, X² für eine
Gruppe -CH₂NY-, wobei Y durch die katalytische Hydrierung in
ein Wasserstoffatom umwandelbare Benzyl-, Benzhydryl- oder
α-Methylbenzylgruppe bedeutet, oder eine Imin-(-CH=N-)-Gruppe
oder eine Gruppe -CONH- steht, X³ für eine Gruppe
-CO(CH₂)₄- oder eine Gruppe -CH₂X⁵- steht, worin X⁵ für
C2-7-Alkenylen oder C2-7-Alkinylen steht, oder worin X²-X³-
eine Gruppe -CH₂N=CH(CH₂)₄- bedeutet und X⁴ für C2-6-Alkenylen
oder C2-6-Alkinylen steht, und die andere Gruppe oder
Gruppen folgende Bedeutung besitzen:
X = -CH₂OR⁶; X¹ = -CH(OH)-; X² = -CH₂NR³; X³ = -(CH₂)₅-; und X⁴ = -(CH₂)₃-, wobei R⁶ und R³ die oben angegebene Bedeutung besitzen, oder ein geschütztes Derivat davon reduziert und anschließend möglicherweise vorhandene Schutzgruppen entfernt; oder - (3) eine Verbindung der allgemeinen Formel:
worin Z für die Gruppe
steht und R⁵ und R⁶, die gleich oder verschieden sein können, jeweils für
ein Wasserstoffatom oder eine Schutzgruppe stehen und L eine
abspaltbare Gruppe bedeutet, mit einem Amin der allgemeinen
Formel:
worin Y¹ ein Wasserstoffatom oder eine durch katalytische
Hydrierung in ein Wasserstoffatom umwandelbare Gruppe bedeutet,
umsetzt und anschließend vorhandene Schutzgruppen ent
fernt,
und gegebenenfalls die erhaltene Verbindung des Anspruchs 1 oder ein Salz davon in ein physiologisch annehmbares Salz überführt.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB838310477A GB8310477D0 (en) | 1983-04-18 | 1983-04-18 | Chemical compounds |
GB838317087A GB8317087D0 (en) | 1983-06-23 | 1983-06-23 | Chemical compounds |
GB838329568A GB8329568D0 (en) | 1983-11-04 | 1983-11-04 | Chemical compounds |
GB848401889A GB8401889D0 (en) | 1984-01-25 | 1984-01-25 | Chemical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
DE3414752A1 DE3414752A1 (de) | 1984-10-18 |
DE3414752C2 true DE3414752C2 (de) | 1993-03-25 |
Family
ID=27449465
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19843414752 Granted DE3414752A1 (de) | 1983-04-18 | 1984-04-18 | Phenethanolamin-verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3448338A Expired - Lifetime DE3448338C2 (de) | 1983-04-18 | 1984-04-18 | |
DE1995175029 Active DE19575029I2 (de) | 1983-04-18 | 1984-04-18 | 4-Hydroxy-1-ÄÄÄ6-(4-phenylbutoxy)-hexalÜ-aminoÜ-methylÜ-1,3-benzoldimenthanol und seine physiologisch annehmbaren Salze |
DE3448452A Expired - Lifetime DE3448452C2 (de) | 1983-04-18 | 1984-04-18 | Phenylalkoxyalkylaminderivate und ihre Verwendung |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3448338A Expired - Lifetime DE3448338C2 (de) | 1983-04-18 | 1984-04-18 | |
DE1995175029 Active DE19575029I2 (de) | 1983-04-18 | 1984-04-18 | 4-Hydroxy-1-ÄÄÄ6-(4-phenylbutoxy)-hexalÜ-aminoÜ-methylÜ-1,3-benzoldimenthanol und seine physiologisch annehmbaren Salze |
DE3448452A Expired - Lifetime DE3448452C2 (de) | 1983-04-18 | 1984-04-18 | Phenylalkoxyalkylaminderivate und ihre Verwendung |
Country Status (37)
Country | Link |
---|---|
US (5) | US4992474A (de) |
JP (2) | JPS63264443A (de) |
KR (1) | KR920004186B1 (de) |
AR (3) | AR244199A1 (de) |
AT (1) | AT390611B (de) |
AU (1) | AU573212B2 (de) |
BE (1) | BE899448A (de) |
BG (1) | BG61490B2 (de) |
CA (2) | CA1335999C (de) |
CH (2) | CH667084A5 (de) |
CY (1) | CY1482A (de) |
CZ (1) | CZ285602B6 (de) |
DE (4) | DE3414752A1 (de) |
DK (2) | DK167493B1 (de) |
ES (2) | ES8505641A1 (de) |
FI (1) | FI85011C (de) |
FR (1) | FR2545482B1 (de) |
GB (2) | GB2140800B (de) |
GR (1) | GR79925B (de) |
HK (1) | HK36889A (de) |
HU (1) | HU200160B (de) |
IE (1) | IE57237B1 (de) |
IL (1) | IL71569A (de) |
IT (1) | IT1199112B (de) |
KE (1) | KE3864A (de) |
LU (2) | LU85329A1 (de) |
MX (1) | MX9203226A (de) |
MY (1) | MY102087A (de) |
NL (2) | NL188406C (de) |
NO (2) | NO159016C (de) |
NZ (2) | NZ207885A (de) |
PH (1) | PH21574A (de) |
PT (1) | PT78443B (de) |
SE (1) | SE462594B (de) |
SG (1) | SG12289G (de) |
SK (1) | SK278120B6 (de) |
ZW (1) | ZW6584A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10249576B3 (de) * | 2002-10-24 | 2004-04-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von (R)-Salbutamol |
Families Citing this family (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
IL74940A (en) | 1984-04-17 | 1988-06-30 | Glaxo Group Ltd | Phenethanolamine compounds,their preparation and pharmaceutical compositions containing them |
GB8525321D0 (en) * | 1985-10-15 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds |
US4943591A (en) * | 1984-10-17 | 1990-07-24 | Glaxo Group Limited | Dichloroaniline derivatives |
GB8525484D0 (en) * | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds |
EP0223410A3 (de) * | 1985-10-16 | 1987-11-19 | Glaxo Group Limited | Ethanolaminderivate |
EP0220054A3 (de) * | 1985-10-16 | 1987-12-02 | Glaxo Group Limited | Ethanolaminderivate |
GB8525483D0 (en) * | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds |
US4959381A (en) * | 1987-02-10 | 1990-09-25 | Glaxo Group Limited | Pyridine compounds which have useful activity associated with reversible air ways obstruction |
JPS6485964A (en) * | 1987-03-12 | 1989-03-30 | Glaxo Group Ltd | Compound |
GB8718940D0 (en) * | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
GB8718938D0 (en) * | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
AU609209B2 (en) * | 1987-11-13 | 1991-04-26 | Glaxo Group Limited | Phenethanolamine derivatives |
DK702188A (da) * | 1987-12-18 | 1989-06-19 | Glaxo Group Ltd | Ethanolaminderivater |
ZA889405B (en) * | 1987-12-18 | 1989-12-27 | Glaxo Group Ltd | Ethanolamine derivatives |
GB2230775A (en) * | 1989-04-24 | 1990-10-31 | Glaxo Group Ltd | Phenethanolamine compounds |
GB8909273D0 (en) * | 1989-04-24 | 1989-06-07 | Glaxo Group Ltd | Chemical compounds |
JPH03178929A (ja) * | 1989-09-07 | 1991-08-02 | Glaxo Group Ltd | 炎症及びアレルギー治療用化合物 |
US5290815A (en) * | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
IL95590A (en) * | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
DK0416950T3 (da) * | 1989-09-08 | 1993-10-11 | Glaxo Group Ltd | Medikamenter |
US5208226A (en) * | 1989-09-08 | 1993-05-04 | Glaxo Group Limited | Medicaments |
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
AU629989B2 (en) * | 1989-10-10 | 1992-10-15 | Glaxo Group Limited | Phenethanolamine derivatives |
SK280967B6 (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Inhalačný prístroj |
US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
UA26230A (uk) | 1990-03-02 | 1999-07-19 | Глексо Груп Лімітед | Іhгалятор для спільhого використаhhя з лікувальhим блоком і лікувальhий блок |
US5919827A (en) * | 1990-07-11 | 1999-07-06 | Sepracor Inc. | Method for treating asthma using optically pure R(-) salmeterol |
GB9026005D0 (en) * | 1990-11-29 | 1991-01-16 | Glaxo Group Ltd | Drug material suitable for micronisation |
CN1056974C (zh) * | 1992-02-11 | 2000-10-04 | 格拉克索公司 | 适宜于微粒化的药物材料的制备方法 |
WO1993016031A1 (en) * | 1992-02-11 | 1993-08-19 | Glaxo Group Limited | Benzenedimethanol derivative suitable for micronisation |
AP323A (en) * | 1992-05-08 | 1994-03-07 | Glaxo Group Ltd | Drug material suitable for micronisation. |
GB9215274D0 (en) * | 1992-07-17 | 1992-09-02 | Scras | Derivatives of(phenylethyl-beta-ol)amine |
ES2065269B1 (es) * | 1993-05-11 | 1995-10-01 | S A L V A T Lab Sa | 6-(4-(fenilbutoxi) hexilaminometil-4-hidroxi-a1,a3-bencenodimetanol. procedimiento para la obtencion del mismo y nuevos intermedios utilizados en su preparacion. |
HU221500B (en) * | 1993-12-10 | 2002-10-28 | Novartis Ag | 3-[6-(4-phenylbutoxy)hexyl]-5-(4-hydroxy-3-hydroxymethylphenyl)-oxazolidine, use thereof, process for preparing it and pharmaceutical compositions containing the same |
GB9507768D0 (en) | 1995-04-13 | 1995-05-31 | Glaxo Group Ltd | Method of apparatus |
DK0820279T3 (da) * | 1995-04-14 | 2002-10-07 | Smithkline Beecham Corp | Dosisudmålende inhalator til Albuterol |
GEP20002266B (en) | 1995-04-14 | 2000-10-25 | Glaxo Wellcome Inc | Metered Dose Inhaler, the Inhaler System Comprising the Same and Method for Treatment of Respiratory Disturbances |
EP1166811B1 (de) | 1995-04-14 | 2006-12-06 | SmithKline Beecham Corporation | Dosierinhalator für Fluticasonepropionat |
WO1996032150A1 (en) | 1995-04-14 | 1996-10-17 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
AU4967997A (en) | 1996-12-02 | 1998-06-29 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same |
US6254882B1 (en) | 1997-09-16 | 2001-07-03 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol |
EA003741B1 (ru) * | 1998-06-01 | 2003-08-28 | Энтони Дж. Вербискар | Местное трансдермальное лечение |
ES2142771B1 (es) * | 1998-09-28 | 2001-01-01 | Vita Invest Sa | Nuevos derivados de la 6-(4-fenil-butoxi) hexilamina y procedimiento para la obtencion de salmeterol. |
WO2000061108A1 (en) | 1999-04-14 | 2000-10-19 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
SK287231B6 (sk) * | 1999-08-21 | 2010-04-07 | Nycomed Gmbh | Liečivo zahŕňajúce PDE inhibítor a agonistu beta2 adrenoreceptora |
GB0009613D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
GB0009609D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic compositions |
GB0014546D0 (en) * | 2000-06-14 | 2000-08-09 | Glaxo Group Ltd | A novel process |
GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
GB0019172D0 (en) * | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
AR032361A1 (es) * | 2000-08-05 | 2003-11-05 | Glaxo Group Ltd | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US20030207057A1 (en) | 2000-09-18 | 2003-11-06 | Britto Ignatius Loy | Metered dose inhaler can coated two or more times with fluorocarbon polymers |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
DE60220887T2 (de) * | 2001-03-08 | 2008-02-28 | Glaxo Group Ltd., Greenford | Agonisten von beta-adrenorezeptoren |
US20040197271A1 (en) * | 2001-03-20 | 2004-10-07 | Kunka Robert Leonard | Inhalation drug combinations |
US7045658B2 (en) | 2001-03-22 | 2006-05-16 | Glaxo Group Limited | Formailide derivatives as beta2-adrenoreceptor agonists |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
US20030055026A1 (en) * | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
WO2002088167A1 (en) * | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
WO2002098404A1 (en) * | 2001-06-01 | 2002-12-12 | Tendskin Company | Topical compositions for veterinary uses |
BRPI0212455B8 (pt) | 2001-09-14 | 2021-05-25 | Glaxo Group Ltd | composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo |
US6680345B2 (en) | 2001-09-14 | 2004-01-20 | Boehringer Ingelheim Pharma Kg | Salicylic acid salts of salmeterol |
JP4199114B2 (ja) * | 2001-09-14 | 2008-12-17 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | サリチル酸塩、その製法及び医薬組成物としての使用 |
WO2003042160A1 (en) * | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
US6756508B2 (en) | 2002-03-04 | 2004-06-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Cinnamic acid salts, processes for their preparation, and their use as medicaments |
AU2003221482A1 (en) * | 2002-03-04 | 2003-09-16 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Novel cinnamate salts, method for production and use thereof as medicaments |
US6835857B2 (en) | 2002-03-05 | 2004-12-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene |
DE10209583B4 (de) * | 2002-03-05 | 2006-01-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von 4-(6-Bromhexyloxy)-butylbenzol |
JP2005533013A (ja) * | 2002-04-19 | 2005-11-04 | イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティ オブ エルサレム | 一酸化窒素供与基および反応性酸素種捕捉基を含有するβ作用薬化合物、ならびに呼吸障害の治療における該化合物の使用 |
DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
AU2003239880A1 (en) | 2002-05-28 | 2003-12-12 | Theravance, Inc. | ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
GB0217225D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
GB0225030D0 (en) * | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
US7442839B2 (en) * | 2002-10-28 | 2008-10-28 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
GB0225535D0 (en) * | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
AU2003293361A1 (en) * | 2002-12-18 | 2004-07-29 | Glaxo Group Limited | Drug delivery system with vented mouthpiece |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
EP1615881A2 (de) * | 2003-04-01 | 2006-01-18 | Theravance, Inc. | Diarylmethyl und verwandte verbindungen mit beta2 adrenergic-rezeptor agonistischer und muscarin-rezeptor antagonistischer aktivität |
US20040226556A1 (en) * | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
EP1626970B1 (de) * | 2003-05-28 | 2009-07-08 | Theravance, Inc. | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten |
TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
US20050026884A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20050113318A1 (en) * | 2003-07-31 | 2005-05-26 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
US20090285900A1 (en) * | 2003-07-31 | 2009-11-19 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
JP4607112B2 (ja) | 2003-08-11 | 2011-01-05 | グラクソ グループ リミテッド | 医薬定量噴霧式吸入器及び前記吸引器に関連する方法 |
GB0319826D0 (en) * | 2003-08-22 | 2003-09-24 | Glaxo Group Ltd | Process |
AU2004268847A1 (en) * | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
TW200526547A (en) * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
GB0324654D0 (en) * | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
GB0324886D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
WO2005051931A2 (en) * | 2003-11-26 | 2005-06-09 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
EP1691782A1 (de) * | 2003-12-03 | 2006-08-23 | Microdrug AG | Medizinisches präparat mit tiotropium |
SE0303570L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt |
GB0329182D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
TW200531692A (en) * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
JP2007528889A (ja) * | 2004-03-12 | 2007-10-18 | シプラ・リミテッド | 吸入製剤 |
WO2005121065A2 (en) * | 2004-06-03 | 2005-12-22 | Theravance, Inc. | DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS |
WO2006014704A1 (en) * | 2004-07-21 | 2006-02-09 | Theravance, Inc. | DIARYL ETHER β2 ADRENERGIC RECEPTOR AGONISTS |
JP2008512470A (ja) * | 2004-09-10 | 2008-04-24 | セラヴァンス, インコーポレーテッド | アミジン置換アリールアニリン化合物 |
CA2581999C (en) | 2004-10-12 | 2013-04-23 | Generics (Uk) Limited | Preparation of suspension aerosol formulations |
EP1949891A1 (de) | 2004-10-12 | 2008-07-30 | Generics (UK) Limited | Verfahren zur Herstellung von Suspensionsaerosolformulierungen, wobei die Partikel durch Fällung im Innenkanister gebildet werden |
GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
ES2265276B1 (es) * | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
DE102005033732B4 (de) * | 2005-05-27 | 2014-02-13 | Grünenthal GmbH | Trennung stereoisomerer N,N-Dialkylamino-2-alkyl-3-hydroxy-3-phenyl-alkane |
WO2007008427A2 (en) * | 2005-07-08 | 2007-01-18 | Xemplar Pharmaceuticals, Llc | Aerosol compositions and methods |
US8429052B2 (en) * | 2005-07-19 | 2013-04-23 | Lincoln National Life Insurance Company | Method and system for providing employer-sponsored retirement plan |
TWI274641B (en) * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine |
US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
PL1937626T3 (pl) | 2005-10-17 | 2016-08-31 | Generics Uk Ltd | Sposób i związki do otrzymywania salmeterolu |
EP1948164A1 (de) | 2005-10-19 | 2008-07-30 | Ranbaxy Laboratories, Ltd. | Pharmazeutische zusammensetzungen mit muscarinischen rezeptor-antagonisten |
BRPI0617673C1 (pt) * | 2005-10-19 | 2012-05-22 | Ranbaxy Lab Ltd | composições de inibidores de fosfodiesterase do tipo iv |
US7731106B2 (en) * | 2006-01-04 | 2010-06-08 | Nano Mist International, Llc | Air driven delivery system for sprayable media |
GB0602778D0 (en) * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
JP2009529539A (ja) * | 2006-03-07 | 2009-08-20 | エンダセア, インコーポレイテッド | 呼吸器障害を治療するための方法および組成物 |
ES2296516B1 (es) * | 2006-04-27 | 2009-04-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
AP2690A (en) | 2006-08-22 | 2013-07-15 | Ranbaxy Laboratoiries Ltd | Matrix metalloproteinase inhibitors |
US20100029728A1 (en) * | 2006-09-22 | 2010-02-04 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
AU2007298549A1 (en) * | 2006-09-22 | 2008-03-27 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
ES2302447B1 (es) * | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2306595B1 (es) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
US20080207659A1 (en) * | 2007-02-15 | 2008-08-28 | Asit Kumar Chakraborti | Inhibitors of phosphodiesterase type 4 |
MX2009009793A (es) | 2007-03-14 | 2009-10-16 | Ranbaxy Lab Ltd | Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa. |
EP2124943A1 (de) * | 2007-03-14 | 2009-12-02 | Ranbaxy Laboratories Limited | Pyrazolo[3,4-b]pyridinderivate als phosphodiesterasehemmer |
US20080319086A1 (en) * | 2007-06-20 | 2008-12-25 | Protia, Llc | Deuterium-enriched salmeterol |
US20090048155A1 (en) | 2007-08-15 | 2009-02-19 | Endacea, Inc. | Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection |
ES2320961B1 (es) | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
EP2222676A4 (de) | 2007-12-21 | 2011-10-26 | Endacea Inc | A1-adenosinrezeptorantagonisten |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
EP2257172A4 (de) * | 2008-02-26 | 2013-07-03 | Elevation Pharmaceuticals Inc | Verfahren und system zur behandlung der chronisch obstruktiver lungenerkrankung durch verabreichung zerstäubter anticholinergika |
EP2111861A1 (de) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Zusammensetzungen von Phosphodiesterase-IV-Hemmern |
CN102014779B (zh) | 2008-05-09 | 2014-10-22 | 赫莱拉公司 | 用于治疗支气管树的系统、组件和方法 |
EP2127641A1 (de) | 2008-05-26 | 2009-12-02 | Inke, S.A. | Mikronisierbare Form von Salmeterolxinafoat |
UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
EP2221055A1 (de) * | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one für die Behandlung von Lungenfunktion |
EP2228368A1 (de) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
CN107412212B (zh) | 2009-05-29 | 2021-01-22 | 珍珠治疗公司 | 经肺递送长效毒蕈碱拮抗剂及长效β2肾上腺素能受体激动剂的组合物及相关方法与系统 |
CN112089394A (zh) | 2009-10-27 | 2020-12-18 | 努瓦拉公司 | 具有可冷却的能量发射组件的递送装置 |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
WO2011060200A1 (en) | 2009-11-11 | 2011-05-19 | Innovative Pulmonary Solutions, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis |
TR201000685A2 (tr) | 2010-01-29 | 2011-08-22 | Bi̇lgi̇ç Mahmut | Salmeterol ve flutikazon içeren farmasötik preparatlar. |
UY33372A (es) | 2010-05-10 | 2011-12-30 | Gilead Sciences Inc | ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?. |
WO2011143106A1 (en) | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bi - functional pyrazolopyridine compounds |
CN103119030A (zh) | 2010-07-30 | 2013-05-22 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
WO2012032546A2 (en) | 2010-09-08 | 2012-03-15 | Cadila Healthcare Limited | Process for the preparation of salmeterol and its intermediates |
CN103228634A (zh) | 2010-09-24 | 2013-07-31 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
EP2578570A1 (de) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Neues Verfahren zur Herstellung von 5-(2-{[6-(2,2-Difluor-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxychinolin-2(1H)-on mittels neuen Synthesezwischenstoffen |
EP2641900A1 (de) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Neuartige polymorphe Kristallformen von 5-(2-{[6-(2,2-difluor-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxychinolin-2(1H)-on, Heminapadisylat als Agonist des beta2-adrenergen Rezeptors |
CN103864629A (zh) * | 2012-12-13 | 2014-06-18 | 天津金耀集团有限公司 | 昔萘酸沙美特罗的精制方法 |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
RU2696582C2 (ru) | 2013-03-15 | 2019-08-05 | Перл Терапьютикс, Инк. | Способы и системы кондиционирования дисперсных кристаллических материалов |
EP2815739B1 (de) | 2013-06-17 | 2019-08-28 | Arven Ilac Sanayi Ve Ticaret A.S. | Inhalationszusammensetzungs-Füllverfahren |
CN104744271B (zh) * | 2013-12-26 | 2016-08-31 | 成都伊诺达博医药科技有限公司 | 一种合成维兰特罗的新工艺 |
US9447067B2 (en) | 2014-10-03 | 2016-09-20 | Amphastar Pahmaceuticals, Inc. | Method of preparing intermediate of salmeterol |
WO2016142582A1 (en) | 2015-03-11 | 2016-09-15 | Fermion Oy | Process for the preparation of crystalline salmeterol and its xinafoate salt |
IL309888A (en) | 2021-07-09 | 2024-03-01 | Astrazeneca Pharmaceuticals Lp | Aerosol drug delivery compounds, methods and systems |
WO2023119093A1 (en) | 2021-12-20 | 2023-06-29 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery |
WO2024006226A1 (en) * | 2022-06-26 | 2024-01-04 | Alexander Shulgin Research Institute, Inc. | N-substituted phenylalkylamines and their use as therapeutic agents |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1451357A (fr) * | 1965-07-01 | 1966-01-07 | Soc Ind Fab Antibiotiques Sifa | Nouveaux alcools dérivés de l'éthano-9, 10 dihydro-9, 10 anthracene et procédé de préparation |
GB1200886A (en) * | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
GB1321701A (en) * | 1969-10-01 | 1973-06-27 | Continental Pharma | Amino-alcohols their salts and process for prepairing the same |
US4137328A (en) * | 1970-07-18 | 1979-01-30 | Pfizer Inc. | Phenyl-alkanolamine, alkylamine and α-aminoalkyl ketone derivatives as heart stimulants |
AT310146B (de) * | 1971-04-26 | 1973-09-25 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen |
US3879442A (en) * | 1972-07-27 | 1975-04-22 | Warner Lambert Co | 5-hydroxy-{60 (substituted aminomethyl)-mu-xylene-{60 ,{60 -diols |
GB1511159A (en) * | 1975-07-10 | 1978-05-17 | Leo A | Amines preparation |
GB1529972A (en) * | 1975-07-29 | 1978-10-25 | Allen & Hanburys Ltd | Basic alcohols |
US4160036A (en) * | 1975-07-29 | 1979-07-03 | Allen & Hanburys Limited | 4-Hydroxy-1,3-benzenedimethanol derivatives |
US4154761A (en) * | 1976-02-09 | 1979-05-15 | Allen & Hanburys Limited | Pharmacologically active compounds |
JPS52113934A (en) * | 1976-03-19 | 1977-09-24 | Eisai Co Ltd | Phenethylamine derivatives and bronchodilator containing the same |
US4233302A (en) * | 1977-12-23 | 1980-11-11 | Glaxo Group Limited | Amine derivatives and pharmaceutical compositions containing them |
DE2833140A1 (de) * | 1978-07-28 | 1980-02-07 | Boehringer Sohn Ingelheim | Neue n-substituierte heterocyclen |
US4160367A (en) * | 1978-09-11 | 1979-07-10 | General Motors Corporation | Dual container additive dispenser for appliance |
DE3061205D1 (en) * | 1979-06-16 | 1983-01-05 | Beecham Group Plc | Secondary amines, their preparation and use in pharmaceutical compositions |
FR2460919A1 (fr) * | 1979-07-11 | 1981-01-30 | Prod Synthese Ste Indle | Amino-ethers oxydes, leur procede de preparation et leur application en therapeutique |
US4288456A (en) * | 1980-09-19 | 1981-09-08 | E. R. Squibb & Sons, Inc. | Compositions containing 1-aryl-5-(2-propenylamino)-1-penten-3-ones and method for treating inflammatory conditions |
US4379166A (en) * | 1981-08-03 | 1983-04-05 | Schering Corporation | Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and heteroarylmethylthio-alkylaminoalcohols |
EP0103830A3 (de) * | 1982-09-22 | 1985-07-31 | Bayer Ag | Wachstumsfördernde Phenylethylamin-Derivate |
ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4985459A (en) * | 1984-02-08 | 1991-01-15 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
IL74940A (en) * | 1984-04-17 | 1988-06-30 | Glaxo Group Ltd | Phenethanolamine compounds,their preparation and pharmaceutical compositions containing them |
-
1984
- 1984-04-17 ZW ZW65/84A patent/ZW6584A1/xx unknown
- 1984-04-18 NZ NZ207885A patent/NZ207885A/xx unknown
- 1984-04-18 GR GR74450A patent/GR79925B/el unknown
- 1984-04-18 SE SE8402188A patent/SE462594B/sv not_active IP Right Cessation
- 1984-04-18 CA CA000452288A patent/CA1335999C/en not_active Expired - Lifetime
- 1984-04-18 PT PT78443A patent/PT78443B/pt unknown
- 1984-04-18 LU LU85329A patent/LU85329A1/fr active Protection Beyond IP Right Term
- 1984-04-18 DE DE19843414752 patent/DE3414752A1/de active Granted
- 1984-04-18 PH PH30586A patent/PH21574A/en unknown
- 1984-04-18 LU LU88265C patent/LU88265I2/xx unknown
- 1984-04-18 DE DE3448338A patent/DE3448338C2/de not_active Expired - Lifetime
- 1984-04-18 HU HU841498A patent/HU200160B/hu unknown
- 1984-04-18 AR AR84296363A patent/AR244199A1/es active
- 1984-04-18 CH CH4750/86A patent/CH667084A5/fr not_active IP Right Cessation
- 1984-04-18 NZ NZ221999A patent/NZ221999A/xx unknown
- 1984-04-18 KR KR1019840002030A patent/KR920004186B1/ko not_active IP Right Cessation
- 1984-04-18 IL IL71569A patent/IL71569A/xx not_active IP Right Cessation
- 1984-04-18 DK DK201784A patent/DK167493B1/da not_active IP Right Cessation
- 1984-04-18 CH CH1977/84A patent/CH661497A5/fr not_active IP Right Cessation
- 1984-04-18 ES ES531722A patent/ES8505641A1/es not_active Expired
- 1984-04-18 GB GB08410124A patent/GB2140800B/en not_active Expired
- 1984-04-18 AU AU27064/84A patent/AU573212B2/en not_active Expired
- 1984-04-18 IE IE965/84A patent/IE57237B1/en not_active IP Right Cessation
- 1984-04-18 NO NO841568A patent/NO159016C/no not_active IP Right Cessation
- 1984-04-18 IT IT48064/84A patent/IT1199112B/it active Protection Beyond IP Right Term
- 1984-04-18 DE DE1995175029 patent/DE19575029I2/de active Active
- 1984-04-18 AT AT0129184A patent/AT390611B/de not_active IP Right Cessation
- 1984-04-18 FI FI841548A patent/FI85011C/fi not_active IP Right Cessation
- 1984-04-18 BE BE0/212786A patent/BE899448A/fr not_active IP Right Cessation
- 1984-04-18 DE DE3448452A patent/DE3448452C2/de not_active Expired - Lifetime
- 1984-04-18 FR FR8406115A patent/FR2545482B1/fr not_active Expired
- 1984-04-18 NL NLAANVRAGE8401258,A patent/NL188406C/xx not_active IP Right Cessation
-
1985
- 1985-01-16 ES ES539625A patent/ES8609209A1/es not_active Expired
-
1986
- 1986-05-21 GB GB08612357A patent/GB2176476B/en not_active Expired
-
1987
- 1987-02-25 AR AR87306841A patent/AR245687A1/es active
- 1987-09-29 MY MYPI87002277A patent/MY102087A/en unknown
-
1988
- 1988-02-25 JP JP63043277A patent/JPS63264443A/ja active Granted
-
1989
- 1989-02-08 AR AR89313169A patent/AR247721A1/es active
- 1989-02-17 KE KE3864A patent/KE3864A/xx unknown
- 1989-02-24 SG SG122/89A patent/SG12289G/en unknown
- 1989-05-04 HK HK368/89A patent/HK36889A/xx not_active IP Right Cessation
- 1989-08-23 US US07/397,664 patent/US4992474A/en not_active Expired - Lifetime
- 1989-12-08 CY CY1482A patent/CY1482A/xx unknown
-
1990
- 1990-06-21 US US07/541,631 patent/US5091422A/en not_active Expired - Lifetime
- 1990-11-29 US US07/619,899 patent/US5126375A/en not_active Expired - Lifetime
-
1991
- 1991-12-19 US US07/810,183 patent/US5243076A/en not_active Expired - Lifetime
- 1991-12-23 SK SK4028-91A patent/SK278120B6/sk unknown
- 1991-12-23 CZ CS914028A patent/CZ285602B6/cs unknown
-
1992
- 1992-02-19 US US07/837,783 patent/US5225445A/en not_active Expired - Lifetime
- 1992-06-24 MX MX9203226A patent/MX9203226A/es unknown
- 1992-08-18 CA CA000616467A patent/CA1336004C/en not_active Expired - Lifetime
- 1992-08-18 JP JP4219484A patent/JPH0729997B2/ja not_active Expired - Lifetime
- 1992-12-30 DK DK199201580A patent/DK175083B1/da not_active IP Right Cessation
-
1993
- 1993-06-11 NL NL930066C patent/NL930066I2/nl unknown
- 1993-08-20 BG BG98059A patent/BG61490B2/bg unknown
-
1994
- 1994-09-22 NO NO1994017C patent/NO1994017I1/no unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10249576B3 (de) * | 2002-10-24 | 2004-04-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von (R)-Salbutamol |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3414752C2 (de) | ||
DE3046719C2 (de) | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel | |
DE3704223C2 (de) | Dichloranilinderivate | |
AT390732B (de) | Pharmazeutika enthaltend pyrazole | |
DD251551A5 (de) | Verfahren zur herstellung eines phenoxyessigsaeurederivates | |
EP0530702A1 (de) | 1,2-Dihydro-2-oxopyridine als Angiotensin II-Antagonisten | |
DE2015573A1 (de) | Ester von alpha-Aminomethyl-3-(hydroxy- oder hydroxymethyl)-4-hydroxybenzyl-alkoholen und Verfahren zu ihrer Herstellung | |
DE10046029A1 (de) | Indazole | |
EP0101574B1 (de) | 2-Substituierte 1-Aminoalkyl-1,2,3,4-tetrahydro-beta-carboline, ihre Herstellung und Verwendung als Arzneimittel | |
DE2313227C3 (de) | Isoindolin-(l)-on-derivate, deren Salze, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen | |
EP0271013B1 (de) | Basisch substituierte Phenylacetonitrile, ihre Herstellung und diese enthaltende Arzneimittel | |
DE2528147A1 (de) | Aromatische ketone, verfahren zu ihrer herstellung und diese ketone enthaltende arzneimittel | |
DE3613573A1 (de) | Cyclopentylether und ihre herstellung sowie pharmazeutische formulierung | |
DE3049959C2 (de) | ||
EP0243905A1 (de) | 1(omega-[bis-(Phenyl)-alkoxy]-alkyl)-4-(di-(phenyl)-methyl)- Piperazine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
DE3634974A1 (de) | Dichloranilinderivate | |
EP0401798B1 (de) | Substituierte Aminoalkylbenzolderivate | |
EP0054873A1 (de) | 3,4-Disubstituierte 1,2,5-Oxadiazol-2-oxide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
EP0345591B1 (de) | Propanolaminderivate | |
DE4118293A1 (de) | Dichloranilinverbindung | |
AT256816B (de) | Verfahren zur Herstellung von neuen substituierten 1-Phenyl-2-aminoalkanolen und deren Säureadditionssalzen | |
EP0003298B1 (de) | 4-Hydroxy-2-benzimidazolin-thion-Derivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel | |
EP0225543A1 (de) | Basisch substituierte Phenylacetaldehyde, ihre Herstellung und diese enthaltende Arzneimittel | |
CH643250A5 (de) | (3-alkylamino-2-hydroxypropoxy)-furan-2-carbonsaeureanilide. | |
AT368126B (de) | Verfahren zur herstellung von neuen substituierten aethanolaminen, und deren salzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
8172 | Supplementary division/partition in: |
Ref document number: 3448338 Country of ref document: DE |
|
Q171 | Divided out to: |
Ref document number: 3448338 Country of ref document: DE |
|
AH | Division in |
Ref document number: 3448338 Country of ref document: DE |
|
D2 | Grant after examination | ||
AH | Division in |
Ref document number: 3448338 Country of ref document: DE |
|
8364 | No opposition during term of opposition | ||
V448 | Application of spc |
Free format text: PRODUCT NAME: SALMETEROLXINAFOAT; REGISTRATION NO/DATE: 25243.00.00, 25243.00.01; 19950707 Spc suppl protection certif: 195 75 029 Filing date: 19950808 |
|
V457 | Spc granted |
Free format text: PRODUCT NAME: SALMETEROLXINAFOAT; REGISTRATION NO/DATE: 25243.00.00, 25243.00.01; 19950707 Spc suppl protection certif: 195 75 029 Filing date: 19950808 |
|
V464 | Spc expired |
Free format text: PRODUCT NAME: SALMETEROLXINAFOAT; REGISTRATION NO/DATE: 25243.00.00, 25243.00.01; 19950707 Spc suppl protection certif: 195 75 029 Filing date: 19950808 |